MLI Education CME Courses

Listening First: Shared Decisions That Build Trust in Pediatric Obesity Care is a CME activity designed to support pediatricians in delivering effective, evidence-based care to children and adolescents with obesity. Despite the growing prevalence and risks of pediatric obesity, many clinicians face barriers such as limited training, low confidence, and discomfort initiating sensitive conversations.

This activity provides practical guidance on guideline-recommended screening, culturally and developmentally appropriate communication strategies, and the development of individualized treatment plans. With a focus on shared decision-making and building trust with families, participants will gain the tools needed to improve patient engagement and outcomes in pediatric obesity care.

This MedHive™ educational initiative focuses on empowering endocrinologists to deliver personalized, evidence-based care for patients with type 2 diabetes. Through interactive peer discussions and expert insights, participants will contribute their collective knowledge to explore strategies to optimize therapy selection, improve adherence, and achieve both glycemic and extra-glycemic goals aligned with the latest 2025 ADA Standards of Care.

Up to 30% of patients with node-positive HR+, HER2- early breast cancer recur within 5 years despite endocrine therapy, which underscores the need for optimized adjuvant strategies. This on-demand program equips medical oncologists with practical, evidence-driven guidance to integrate CDK4/6 inhibitors into individualized treatment plans.

Through expert-led, case-based discussions, participants will review pivotal and emerging data (including monarchE and NATALEE), apply NCCN/ASCO/ESMO recommendations, refine recurrence risk stratification, and strengthen approaches to toxicity management, dose modification, and long-term adherence. Downloadable clinical algorithms and toxicity management tools support immediate implementation in practice.

NTM-LD is a rare but serious condition, most commonly caused by Mycobacterium avium complex (MAC), and disproportionately affects patients with underlying lung diseases such as bronchiectasis, chronic obstructive pulmonary disease (COPD), and asthma—leading to delayed diagnosis, progressive lung damage, and diminished quality of life.

Unlike traditional lectures, this Dialogues program brings attendees into the conversation. Through real-time audience interaction, multidisciplinary expert insights, and real-world patient cases, you’ll explore the complexities of NTM-LD alongside leading specialists in an engaging, studio-quality format. This expert-led activity will include discussion and audience-driven dialogue as participants will examine current and emerging treatment strategies, including approaches for recurrent infection, and explore how evidence-based therapeutic decision-making can optimize clinical outcomes and improve patient quality of life.

This activity is derived from a Live Symposium at ATS 2026, originally held on May 19, 2026.

HCC in the Real World: Evolving Paradigms for High-Risk Patients is a CME activity designed for US-based medical oncologists, gastrointestinal oncologists, hepatologists, gastroenterologists, advanced practice providers, nurses, and other healthcare professionals involved in the treatment and collaborative management of hepatocellular carcinoma (HCC). This educational initiative focuses on the evolving role of frontline immune checkpoint inhibitor (ICI)-based therapies, with emphasis on applying recent prospective data in higher-risk patient populations. Learners will enhance their ability to integrate liver reserve assessment with tumor burden and mortality risk to individualize treatment selection and monitoring, while also strengthening shared decision-making strategies that incorporate patient-specific clinical and functional factors to optimize frontline ICI therapy outcomes in HCC.

Sharper Focus on Geographic Atrophy: Imaging-Based Strategies for Retina Specialists is an educational initiative designed to equip retina specialists, comprehensive ophthalmologists, and other members of the multidisciplinary ophthalmology care team with practical, evidence-based strategies for the diagnosis, monitoring, and management of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Despite advances in retinal imaging and the emergence of complement inhibitor therapies, GA remains underrecognized and inconsistently managed in clinical practice. Variability in the interpretation of multimodal imaging, the lack of standardized monitoring, and gaps in understanding the complement system’s role in disease progression continue to challenge coordinated, patient-centered care. Delayed referral, limited patient understanding of the disease course, and barriers to adherence with monitoring schedules can further delay timely intervention and complicate long-term management.

This activity is derived from a Live ISS at ASRS, originally held on July 17, 2026.

This activity addresses these gaps by reviewing the clinical and multimodal imaging features that distinguish early and intermediate AMD from GA, the lesion-progression patterns that signal worsening disease, and the role of complement dysregulation in GA pathogenesis. Faculty will also examine the mechanisms of action, candidate selection, and integration of complement inhibitor therapies into evidence-based care pathways for patients with GA secondary to AMD.

Through expert-led, case-based discussion, participants will strengthen their ability to interpret imaging findings with greater confidence, implement structured monitoring strategies, and deliver more coordinated, individualized care. Faculty will anchor the discussion in multimodal imaging and use animations of disease pathophysiology and treatment mechanisms, interactive Q&A, and collaborative problem-solving, closing with key takeaways and practical tips for GA monitoring. The program is delivered as a live, interactive industry-supported symposium (ISS) and is intended for retina specialists and other members of the multidisciplinary ophthalmology care team involved in the management of GA secondary to AMD in the United States.

MPN care is advancing fast, but translating molecular findings, prognostic scores, and symptom data into a coherent, risk-adapted plan remains a real challenge at the point of care. This symposium gives the full care team a practical framework — so you can stratify risk accurately, select therapy with confidence, and personalize treatment across PV, ET, and MF. As novel mechanisms of action, combination regimens, and anemia-targeting therapies enter the MPN landscape, clinicians face growing uncertainty about where each option fits. Learn to evaluate emerging and established therapies side by side, anticipate and manage adverse events, and deliver comprehensive, longitudinal care that improves outcomes.

This expert-exchange activity is designed for hematologists/oncologists in academic and community settings and their multidisciplinary teams who manage pediatric and adult patients with acute lymphoblastic leukemia (ALL). Through candid faculty dialogue, the program examines recent clinical advances in induction/consolidation regimens, targeted therapies, and immunotherapies, along with the expanding role of MRD-guided decision-making across the disease continuum. Participants will explore how to translate the latest evidence into personalized, risk-adapted treatment plans for patients with Philadelphia chromosome–positive (Ph+) and Ph-negative (Ph−) B-ALL, and how to implement effective monitoring and management strategies for treatment-related adverse events. By addressing persistent gaps in therapy selection and sequencing, this activity aims to improve remission durability, reduce avoidable toxicity, and optimize long-term outcomes in real-world practice.

This activity is derived from a Live ISS at SOHO, originally held on September 10, 2026

UTI at the Point of Care: Diagnostic and Treatment Decisions That Matter is a blended-learning curriculum designed for primary care clinicians, urologists, gynecologists, and other members of the health care team who treat patients with uncomplicated urinary tract infections (uUTIs). Although uUTIs are among the most common infections prompting antibiotic use, nearly half of prescriptions remain inappropriate or non–guideline-concordant. Through interactive, case-based discussion with expert faculty and peers, participants will practice distinguishing uUTI from asymptomatic bacteriuria, complicated UTI, and pyelonephritis. Participants will review guideline-concordant regimens, including novel agents, informed by local resistance patterns and antimicrobial stewardship principles. Participants will also apply risk-based stratification to guide urine culture use and therapy selection. Finally, participants will develop patient-centered strategies that reduce the burden of uUTIs on patients and the health care system.

This MedHive™ workshop convenes expert faculty in a case-based, peer-driven format to help interprofessional teams individualize hepatocellular carcinoma (HCC) treatment while preserving hepatic reserve and quality of life. Faculty will translate clinical trial and real-world evidence into practical selection among immune checkpoint inhibitor (ICI)–based regimens for advanced disease, including in patients with impaired liver function or other high-risk features. Throughout, faculty will model multidisciplinary coordination, shared decision-making, and structured monitoring of liver function and treatment-related toxicity across the care continuum.

This educational initiative focuses on empowering HCPs to optimize individualized care for patients with Type 2 diabetes (T2D). The interactive Real Answers to Real Questions format will integrate extensive peer-to-peer discussion into didactic presentation elements and provide clinicians with the opportunity to examine the latest clinical data and scientific advancements related to once-weekly basal insulins poised to enter the treatment armamentarium for this disease. By tackling real-world, practical questions that clinicians face every day, the activity will enhance HCPs’ confidence in the application of novel weekly basal insulins in routine practice when they become available, ultimately advancing equitable, patient-centered outcomes in T2D care.

Advancing the Pediatric to Adult Continuum in IBS-C: Evidence-Based Treatment and Transitions of Care is a continuing medical education (CME) activity designed for US-based pediatric and adult gastroenterologists, nurse practitioners, physician assistants, GI nursing professionals, transition coordinators, and behavioral health specialists involved in the care of patients with IBS-C. This activity focuses on applying evidence-based approaches to the selection, initiation, dosing, and monitoring of newly approved and emerging therapeutic agents in pediatric patients aged 7 to 17 years, including effective management of adverse effects. In addition, it will provide learners with a structured framework to support safe and effective transition of adolescents with IBS-C to adult care, emphasizing readiness assessment, care coordination, and continuity of medication therapy to optimize long-term patient outcomes.

This educational activity features 10 two-minute videos addressing key unmet needs in the management of relapsed/refractory multiple myeloma (RRMM), with a focus on cereblon E3 ligase modulators (CELMoDs). Topics include the role of cereblon in myeloma biology and IMiD resistance, CELMoD mechanism of action, strategies for overcoming resistance, and rational combinations with backbone agents; clinical evidence supporting novel iberdomide- and mezigdomide-containing regimens; evolving sequencing strategies with CELMoDs, CAR T-cell therapy, and bispecific antibodies; and practical approaches to mitigating adverse events associated with CELMoD-based combinations. Collectively, this video series is designed to provide clinicians with current, evidence-based guidance to support treatment selection, combination and sequencing decisions, and toxicity management for patients with RRMM.

Applied Judgment in Early Symptomatic Alzheimer’s Disease: Eligibility, Safety, and Shared Decision-Making is a CME-certified, case-based educational program designed to equip clinicians with the practical skills needed to integrate anti-amyloid monoclonal antibody therapies into real-world care. In response to the rapid evolution of Alzheimer’s disease (AD) treatment and the shift toward biologically guided, risk-stratified management, this activity addresses critical gaps in clinician readiness related to patient selection, biomarker confirmation, safety monitoring, and multidisciplinary coordination. Through interactive, peer-driven learning, participants will strengthen their ability to identify appropriate candidates using evidence-based eligibility and triage criteria, interpret and manage amyloid-related imaging abnormalities (ARIA), and apply patient-centered shared decision-making strategies. The program emphasizes real-world application through case scenarios, role-specific tools, and collaborative discussion, enabling learners to align treatment decisions with patient values while ensuring safe and effective longitudinal care. This activity is designed for US-based neurologists, dementia specialists, and advanced practice providers (NPs and PAs) involved in the care of patients with AD. By enhancing applied clinical judgment and team-based care strategies, the program aims to reduce variability in practice, improve patient-centered outcomes, and bridge the gap between clinical trial evidence and everyday implementation.

The Primary Care Playbook for Obesity: Evidence, Engagement, and Effective Management is designed for primary care physicians, physician associates, and nurse practitioners involved in the care of patients with obesity in the United States. This activity addresses persistent gaps in the diagnosis and long-term management of obesity, including inconsistent application of evidence-based criteria and underutilization of effective therapies. Participants will build skills in accurate identification and documentation of obesity, as well as the use of structured, person-first communication to support patient engagement. The program also focuses on selecting individualized, evidence-based treatment plans and implementing longitudinal management strategies that incorporate counseling, pharmacotherapy, and shared decision-making.

Beyond Daily Injections: Implementing Once-Weekly Basal Insulin to Simplify and Personalize Care is designed for US-based endocrinologists and endocrinology-focused NPs and PAs involved in the management of patients with type 2 diabetes (T2D). Once-weekly basal insulin regimens are poised to enter the treatment armamentarium for diabetes management. Gaps in understanding the unique molecular design and pharmacology of, and latest clinical data on these novel formulations may contribute to therapeutic inertia and delayed implementation of a more convenient, flexible, and potentially safer alternative to daily insulin regimens for patients with T2D.

This interactive Real Answers to Real Questions CME activity will integrate extensive peer-to-peer discussion into didactive presentation elements and provide clinicians with the opportunity to examine the recent scientific advancements related to once-weekly basal insulins and compare their pro and cons with traditional once-daily basal insulin regimens. By tackling real-world, practical questions that endocrinologists and endocrinology-focused NPs and PAs face every day, the activity will prepare these clinicians to confidently integrate once-weekly basal insulins into patient-centered diabetes care when they become available.